Granted Patent
B2
US 12,246,023 · App. 18/389,771 · Granted Mar 11, 2025
Use of reboxetine to treat narcolepsy
Assignee:
AXSOME THERAPEUTICS, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
Claims (13)
1. A method of treating sleep apnea, comprising administering reboxetine to a human being in need thereof.
2. The method of claim 1 , wherein the human being has mild sleep apnea.
3. The method of claim 1 , wherein the human being has less than 15 events of sleep apnea per hour.
4. The method of claim 1 , wherein the human being has moderate sleep apnea.
5. The method of claim 1 , wherein the human being has less than 30 events of sleep apnea per hour.
6. The method of claim 1 , wherein a daily dose of about 0.0015 mmol to about 0.08 mmol of reboxetine is administered to the human being.
7. The method of claim 1 , wherein reboxetine is administered once a day.
8. The method of claim 1 , wherein reboxetine is administered twice a day.
9. The method of claim 1 , wherein reboxetine is administered in a dosage form further containing a polymer.
10. The method of claim 1 , wherein reboxetine is administered in a dosage form further containing a binder.
11. The method of claim 1 , wherein reboxetine is administered in a dosage form further containing a lubricant.
12. The method of claim 1 , wherein reboxetine is administered in a dosage form further containing a diluent.
13. The method of claim 1 , wherein reboxetine is administered in a dosage form further containing a disintegrant.
Assignments (2)
SECURITY INTEREST
Recorded May 9, 2025
From: AXSOME THERAPEUTICS, INC.; AXSOME MALTA LTD.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 071247/0836 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 9, 2024
From: TABUTEAU, HERRIOT
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 066068/0065 →
Continuity (7)
Continuation In Part
PCTUS2019056134
· Oct 14, 2019
Provisional Application
62946295
· Dec 10, 2019
Provisional Application
62943077
· Dec 3, 2019
Provisional Application
62745956
· Oct 15, 2018
References Cited (119)
US 6228398B1
· Devane et al.
· 2001
[cited by applicant]
US 6395788B1
· Inglehart
· 2002
[cited by applicant]
US 6441038B1
· Loder et al.
· 2002
[cited by applicant]
US 6465458B1
· Wong et al.
· 2002
[cited by applicant]
US 6485746B1
· Campbell et al.
· 2002
[cited by applicant]
US 6610690B2
· Wong et al.
· 2003
[cited by applicant]
US 6622036B1
· Suffin
· 2003
[cited by applicant]
US 6632451B2
· Penhasi et al.
· 2003
[cited by applicant]
US 6642235B2
· Wong et al.
· 2003
[cited by applicant]
US 6703389B2
· Wong et al.
· 2004
[cited by applicant]
US 6987107B2
· Wong et al.
· 2006
[cited by applicant]
US 7241762B2
· Wong et al.
· 2007
[cited by applicant]
US 7276503B2
· Wong et al.
· 2007
[cited by applicant]
US 7317011B2
· Wong et al.
· 2008
[cited by applicant]
US 7338953B2
· Wong et al.
· 2008
[cited by applicant]
US 7723334B2
· Wong et al.
· 2010
[cited by applicant]
US 8383681B2
· Roberts et al.
· 2013
[cited by applicant]
US 8512751B2
· Rariy et al.
· 2013
[cited by applicant]
US 8562951B2
· Suffin et al.
· 2013
[cited by applicant]
US 9034874B2
· Auberson et al.
· 2015
[cited by applicant]
US 9211293B2
· Deaver et al.
· 2015
[cited by applicant]
US 9216182B2
· Wang et al.
· 2015
[cited by applicant]
US 9359290B2
· Khayrallah et al.
· 2016
[cited by applicant]
US 9624192B2
· Auberson et al.
· 2017
[cited by applicant]
US 9750734B2
· Mouthon et al.
· 2017
[cited by applicant]
US 9763884B2
· Bloemers et al.
· 2017
[cited by applicant]
US 20030040464A1
· Wong et al.
· 2003
[cited by applicant]
US 20050250803A1
· Glue et al.
· 2005
[cited by applicant]
US 20060039890A1
· Renshaw et al.
· 2006
[cited by applicant]
US 20080020039A1
· Parikh et al.
· 2008
[cited by applicant]
US 20080103145A1
· Wong et al.
· 2008
[cited by applicant]
US 20080261984A1
· Hughes et al.
· 2008
[cited by applicant]
US 20090023705A1
· Roberts et al.
· 2009
[cited by applicant]
US 20090275562A1
· Rao et al.
· 2009
[cited by applicant]
US 20100160294A1
· Rao et al.
· 2010
[cited by applicant]
US 20110052648A1
· Avramoff et al.
· 2011
[cited by applicant]
US 20120035121A1
· Rudnic et al.
· 2012
[cited by applicant]
US 20130017262A1
· Mullen et al.
· 2013
[cited by applicant]
US 20140275244A1
· Khayrallah et al.
· 2014
[cited by applicant]
US 20160244426A1
· Auberson et al.
· 2016
[cited by applicant]
US 20190381056A1
· Tabuteau
· 2019
[cited by applicant]
US 20200147093A1
· Tabuteau
· 2020
[cited by applicant]
US 20200147095A1
· Tabuteau
· 2020
[cited by applicant]
US 20200147096A1
· Tabuteau
· 2020
[cited by applicant]
US 20210015823A1
· Tabuteau
· 2021
[cited by applicant]
US 20210100808A1
· Tabuteau
· 2021
[cited by applicant]
US 20220249501A1
· Tabuteau
· 2022
[cited by applicant]
CL 200001765
· 2001
[cited by applicant]
CL 200802868
· 2009
[cited by applicant]
EP 1632235A2
· 2006
[cited by applicant]
EP 1536791B1
· 2010
[cited by applicant]
EP 2514417A2
· 2012
[cited by applicant]
WO 1995028148A1
· 1995
[cited by applicant]
WO 2001001973A2
· 2001
[cited by applicant]
WO 0039072
· 2001
[cited by applicant]
WO 0147503A1
· 2001
[cited by applicant]
WO 0162236A2
· 2001
[cited by applicant]
WO 2006069030A1
· 2006
[cited by applicant]
WO 2008137923A2
· 2008
[cited by applicant]
WO 2009049215A1
· 2009
[cited by applicant]
WO 2009062318A1
· 2009
[cited by applicant]
WO 2011107749A2
· 2011
[cited by applicant]
WO 2011107750A2
· 2011
[cited by applicant]
WO 2011107755A2
· 2011
[cited by applicant]
WO 2018200775A1
· 2018
[cited by applicant]
WO 2019245975A1
· 2019
[cited by applicant]
WO 2020081461A1
· 2020
[cited by applicant]
Larrosa, O. et al., Stimulant and Anticataplectic Effects of Reboxetine in Patients with Narcolepsy: A Pilot Study, Sleep, 24(3), 282-285, May 2001.
[cited by applicant]
Summary of Product Characteristics, EDRONAX (reboxetine), last updated on UK electronic Medicines Compendium (eMC), Oct. 23, 2015.
[cited by applicant]
Hajos, M. et al., The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile, CNS Drug Reviews, 10(1), 23-44, Mar. 2004.
[cited by applicant]
Schmidt, C. et al., The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram, Behavioural Brain Research, 308, 205-210, J…
[cited by applicant]
Sepede, G. et al., Reboxetine in clinical practice: a review, Clin Ter., 163(4), e255-e262, Jul. 2012.
[cited by applicant]
U.S. National Library of Medicine, ClinicalTrials.gov Identifier NCT03881852, Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT), 2019; downloaded from: https://clinicaltrials…
[cited by applicant]
Aloe, F. et al., Brazilian guidelines for the treatment of narcolepsy, Brazilian Journal of Psychiatry, 32(3), 305-314, Sep. 2010.
[cited by applicant]
Doksat et al., A Case of Profound Weight Loss Secondary to use of Reboxetine, J Child Adolesc Behav 2014, 2:3, 2014.
[cited by applicant]
Shands, Drugs & Therapy Bulletin, vol. 21, No. 10, 2007.
[cited by applicant]
Preetha et al., Biphasic Drug Delivery in Controlled Release Formulations—A Review. IJ PT, 6(4), 3046-3060, Apr. 2015.
[cited by applicant]
Edronax, Package Leaflet: Information for the User, 2020.
[cited by applicant]
Sankar et al., What is a missed dose? Implications for construct validity and patient adherence, AIDS Care, 19(6), 775-780, Jul. 2007.
[cited by applicant]
Tabuteau, International Search Report and Written Opinion, PCT/US 2019/056134, mailed Jan. 30, 2020.
[cited by applicant]
Daniels et al., Health-related quality of life in narcolepsy, J. Sleep Res., 10(1), 75-81, Mar. 2001.
[cited by applicant]
Tabuteau, International Search Report and Written Opinion, PCT/US2019/037500, mailed Oct. 31, 2019.
[cited by applicant]
Tabuteau, International Preliminary Report on Patentability, PCT/US2019/037500, mailed Dec. 30, 2020.
[cited by applicant]
Sateia et al., International Classification of Sleep Disorders, Chest, 146(5), 1387-1394, Nov. 2014.
[cited by applicant]
Kallweit et al., Patient-Reported Measures of Narcolepsy: The Need for Better Assessment, Journal of Clinical Sleep Medicine, 13(5), 737-744, 2017.
[cited by applicant]
Tabuteau, International Search Report and Written Opinion, PCT/US2020/062560, mailed Feb. 18, 2021.
[cited by applicant]
Tabuteau, International Preliminary Report on Patentability, PCT/US2019/056134, mailed Apr. 29, 2021.
[cited by applicant]
Thorpy, Recently Approved and Upcoming Treatments for Narcolepsy, CNS Drugs, 34: 9-27, 2020.
[cited by applicant]
Szabo et al., Neurobiological and Immunogenetic Aspects of Narcolepsy: Implications for Pharmacotherapy, Sleep Med Rev. 43: 23-36, Feb. 2019.
[cited by applicant]
Hublin et al., The Ullanlinna Narcolepsy Scale: validation of a measure of symptoms in the narcoleptic syndrome, Journal of Sleep Research, 3(1), 52-59, Mar. 1994.
[cited by applicant]
Ullanlinna Narcolepsy Scale; the printable version accessed online at: healthysleep.med.harvard.edu/narcolepsy/diagnosing-narcolepsy/narcolepsy-self-evaluation, content last updated Feb. 2018.
[cited by applicant]
European Extended Search Report and Written Opinion for related application 19874099.5, dated Dec. 7, 2021.
[cited by applicant]
Garcia-Borreguero, D. et al., Effects of Reboxetine in Narcolepsy-Cataplexy: Preliminary findings on 14 patients, Sleep, vol. 24, No. Abstract Supplement, pp. A323-A324, Jun. 2001.
[cited by applicant]
O'Gorman, C. et al., Scientific Rational and Clinical Development of AXS-12 for Narcolepsy, Sleep, vol. 42, No. Abstract Supplement, p. A24, Jan. 2019.
[cited by applicant]
Szakacs, Z. et al., Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial, The Lancet Neurology, 16(3), 200-207, Mar. 2017.
[cited by applicant]
Berro, L.F. et al., A journey through narcolepsy diagnosis: From ICSD 1 to ICSD 3, Sleep Science, 7(1), Mar. 2014.
[cited by applicant]
Tabuteau, International Preliminary Report on Patentability, PCT/US2020/062560, mailed Jun. 16, 2022.
[cited by applicant]
Lehert, P. et al., Comparing symptom measurement tools in pediatric narcolepsy, Sleep Epidemiology, 2:100032, Dec. 2022.
[cited by applicant]
Arnold et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clinical therapeutics. Aug. 1, 2010;32(9): 1618-32.
[cited by applicant]
Lal et al. Excessive daytime sleepiness in obstructive sleep apnea. Mechanisms and clinical management. Annals of the American Thoracic Society. May 2021; 18(5): 757-68.
[cited by applicant]
Weaver et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep. Jun. 1, 2007;30(6):711-9.
[cited by applicant]